Wells Fargo
ELTX icon

Wells Fargo’s Elicio Therapeutics ELTX Stock Holding History

Wells Fargo’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.2K Buy
+11,823
New +$119K ﹤0.01% 5734
2026
Q1 		– Sell
-200
Closed -$1.59K – 7267
2025
Q4 		$1.59K Hold
200
– – ﹤0.01% 6246
2025
Q3 		$2.19K Buy
+200
New +$2.02K ﹤0.01% 6176
2024
Q2 		– Sell
-50
Closed -$380 – 7054
2024
Q1 		$380 Buy
50
+7
+16% +$35 ﹤0.01% 6346
2023
Q4 		$359 Buy
43
+21
+95% +$137 ﹤0.01% 6456
2023
Q3 		$186 Buy
22
+7
+47% +$67 ﹤0.01% 6605
2023
Q2 		$143 Hold
15
– – ﹤0.01% 6789
2023
Q1 		$86 Hold
15
– – ﹤0.01% 6966
2022
Q4 		$118 Buy
15
+1
+7% +$9 ﹤0.01% 6757
2022
Q3 		$0 Sell
14
-4
-22% -$42 ﹤0.01% 6813
2022
Q2 		$0 Sell
18
-478
-96% -$7.63K ﹤0.01% 6961
2022
Q1 		$10K Sell
496
-1,164
-70% -$26.3K ﹤0.01% 6260
2021
Q4 		$48K Buy
1,660
+1,642
+9,122% +$83K ﹤0.01% 5982
2021
Q3 		$2K Buy
18
+8
+80% +$864 ﹤0.01% 6562
2021
Q2 		$1K Sell
10
-181
-95% -$26.1K ﹤0.01% 6650
2021
Q1 		$35K Buy
+191
New +$36.9K ﹤0.01% 5981

Other funds holding ELTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo's ELTX Position: Q2 2026 in Review

Wells Fargo opened a new position in Elicio Therapeutics (ELTX) in Q2 2026: 11,823 shares worth $46.2K. The stake represents ﹤0.01% of the portfolio and ranks #5734 among its holdings. This is a return to the name: Wells Fargo previously reported a position in ELTX as recently as Q4 2025.

Wells Fargo first reported a position in ELTX in Q1 2021 and has held it in 16 quarters since. The position peaked at $48K in Q4 2021. 46 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

  • Wells Fargo held 11,823 shares of Elicio Therapeutics worth $46.2K as of Q2 2026.
  • Elicio Therapeutics was a new Wells Fargo position in Q2 2026.
  • Elicio Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #5734 holding.
  • Wells Fargo first reported a position in Elicio Therapeutics in Q1 2021 and has held it in 16 quarters since.
  • Wells Fargo's Elicio Therapeutics position peaked at $48K in Q4 2021.
  • 46 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.